Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
41.15 INR | -2.33% | -2.26% | -7.05% |
05-29 | Link Pharma Chem Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024 | CI |
03-18 | Link Pharma Chem Sells Office in Vadodara, India | MT |
Valuation
Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capitalization 1 | 122.3 | 110.6 | 75.71 | 105 | 178.7 | 162.6 |
Enterprise Value (EV) 1 | 147.4 | 135 | 90.73 | 93.09 | 233.8 | 249.2 |
P/E ratio | 10.8 x | 16.8 x | 7.97 x | 9.68 x | 9.5 x | 24.9 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | 0.52 x | 0.45 x | 0.3 x | 0.3 x | 0.33 x | 0.42 x |
EV / Revenue | 0.63 x | 0.55 x | 0.36 x | 0.27 x | 0.44 x | 0.64 x |
EV / EBITDA | 5.19 x | 6.3 x | 2.64 x | 2.97 x | 6.68 x | 9.17 x |
EV / FCF | 9.03 x | 317 x | -27.1 x | 3.45 x | -7.91 x | -8.7 x |
FCF Yield | 11.1% | 0.32% | -3.69% | 29% | -12.6% | -11.5% |
Price to Book | 1.25 x | 1.07 x | 0.66 x | 0.84 x | 1.23 x | 1.08 x |
Nbr of stocks (in thousands) | 4,441 | 4,441 | 4,441 | 4,441 | 4,441 | 4,441 |
Reference price 2 | 27.55 | 24.90 | 17.05 | 23.65 | 40.25 | 36.61 |
Announcement Date | 29/05/18 | 26/08/19 | 26/08/20 | 02/08/21 | 12/07/22 | 28/08/23 |
Income Statement Evolution (Annual data)
Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net sales 1 | 235.8 | 245 | 254.7 | 348.1 | 535.6 | 387.6 |
EBITDA 1 | 28.38 | 21.44 | 34.4 | 31.36 | 35.02 | 27.18 |
EBIT 1 | 19.79 | 12.49 | 25.12 | 22.62 | 25.74 | 17.95 |
Operating Margin | 8.39% | 5.1% | 9.86% | 6.5% | 4.81% | 4.63% |
Earnings before Tax (EBT) 1 | 13.71 | 9.301 | 14.41 | 16.78 | 26.22 | 8.864 |
Net income 1 | 11.35 | 6.581 | 9.499 | 10.85 | 18.82 | 6.542 |
Net margin | 4.81% | 2.69% | 3.73% | 3.12% | 3.51% | 1.69% |
EPS 2 | 2.556 | 1.482 | 2.139 | 2.443 | 4.238 | 1.473 |
Free Cash Flow 1 | 16.32 | 0.4257 | -3.345 | 27 | -29.57 | -28.64 |
FCF margin | 6.92% | 0.17% | -1.31% | 7.76% | -5.52% | -7.39% |
FCF Conversion (EBITDA) | 57.52% | 1.99% | - | 86.1% | - | - |
FCF Conversion (Net income) | 143.85% | 6.47% | - | 248.89% | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 29/05/18 | 26/08/19 | 26/08/20 | 02/08/21 | 12/07/22 | 28/08/23 |
Balance Sheet Analysis
Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net Debt 1 | 25.1 | 24.4 | 15 | - | 55 | 86.6 |
Net Cash position 1 | - | - | - | 11.9 | - | - |
Leverage (Debt/EBITDA) | 0.8843 x | 1.139 x | 0.4365 x | - | 1.572 x | 3.188 x |
Free Cash Flow 1 | 16.3 | 0.43 | -3.34 | 27 | -29.6 | -28.6 |
ROE (net income / shareholders' equity) | 12.3% | 6.53% | 8.71% | 9.04% | 13.9% | 4.43% |
ROA (Net income/ Total Assets) | 7.2% | 4.44% | 8.49% | 6.26% | 5.85% | 3.65% |
Assets 1 | 157.5 | 148.4 | 111.8 | 173.3 | 321.7 | 179.1 |
Book Value Per Share 2 | 22.00 | 23.40 | 25.70 | 28.30 | 32.60 | 33.90 |
Cash Flow per Share 2 | 0.1800 | 0.0600 | 4.210 | 9.510 | 0.6000 | 0.2100 |
Capex 1 | 11.7 | 8.79 | 17.1 | 18.1 | 11.6 | 8.93 |
Capex / Sales | 4.97% | 3.59% | 6.73% | 5.19% | 2.16% | 2.3% |
Announcement Date | 29/05/18 | 26/08/19 | 26/08/20 | 02/08/21 | 12/07/22 | 28/08/23 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
-7.05% | 2.19M | |
+2.46% | 102B | |
-8.98% | 60.79B | |
+74.76% | 48.86B | |
+13.97% | 37.96B | |
+4.56% | 32.37B | |
+14.72% | 20.64B | |
+11.17% | 16.58B | |
+8.81% | 13.93B | |
-3.19% | 13.25B |
- Stock Market
- Equities
- LINKPH6 Stock
- Financials Link Pharma Chem Limited